
June 9 (Reuters) - Axsome Therapeutics Inc AXSM.O:
AXSOME THERAPEUTICS PROVIDES UPDATE ON THE NEW DRUG APPLICATION (NDA) FOR AXS-14 FOR THE MANAGEMENT OF FIBROMYALGIA
AXSOME THERAPEUTICS INC - RECEIVES REFUSAL TO FILE LETTER FROM FDA FOR AXS-14
AXSOME THERAPEUTICS INC - FDA FINDS NDA FOR AXS-14 INSUFFICIENTLY COMPLETE FOR REVIEW
AXSOME THERAPEUTICS INC - TO CONDUCT ADDITIONAL CONTROLLED TRIAL FOR AXS-14 IN Q4 2025